Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Tomomi Ikemoto is active.

Publication


Featured researches published by Tomomi Ikemoto.


Journal of Organic Chemistry | 2010

Imide-catalyzed oxidation system: sulfides to sulfoxides and sulfones.

Naohiro Fukuda; Tomomi Ikemoto

A new combination system, the oxidation of sulfides using aqueous NaOCl in the presence of a catalytic amount of imide under two-phase conditions, has been developed. The combination effectively converts various sulfides to the corresponding sulfoxides and sulfones. It was deduced that the imide could react with NaOCl to produce N-chloroimide, which would play roles of both the active oxidizing reagent and phase transfer catalyst.


Tetrahedron-asymmetry | 2003

Practical synthesis of (R)-(+)-6-(1,4-dimethoxy-3-methyl-2-naphthyl)-6-(4-hydroxyphenyl)hexanoic acid: a key intermediate for a therapeutic drug for neurodegenerative diseases

Tatsuya Ito; Tomomi Ikemoto; Toru Yamano; Yukio Mizuno; Kiminori Tomimatsu

Abstract A practical method for the preparation of ( R )-(+)-6-(1,4-dimethoxy-3-methyl-2-naphthyl)-6-(4-hydroxyphenyl)hexanoic acid ( R )- 2 , a key intermediate for a therapeutic drug for neurodegenerative diseases, has been developed. rac -Methyl 6-(1,4-dimethoxy-3-methyl-2-naphthyl)-6-(4-(propionyloxy)phenyl) hexanoate rac - 9b was synthesized from 2-methylnaphthoquinone in seven steps. An optically active ester ( R )- 9b was readily obtained from the corresponding racemic ester by lipase-catalyzed resolution, followed by sulfation or phosphorylation. Sulfation by a sulfur trioxide pyridine complex or phosphorylation by phosphoryl chloride enabled facile isolation of the optically active ester simply by extraction. Optically active acid ( R )- 2 was synthesized in excellent enantiomeric excess by hydrolysis of ( R )- 9b followed by recrystallization. The present synthesis of ( R )- 2 was accomplished in 10 steps without requiring chromatographic purification.


Tetrahedron | 2002

Large-scale synthesis of new cyclazines, 5-thia-1,8b-diazaacenaphthylene-3-carboxylic acid derivatives having the peripheral 12π-electron ring system

Tomomi Ikemoto; Tetsuji Kawamoto; Hiroki Wada; Toru Ishida; Tatsuya Ito; Yasushi Isogami; Yoshiko Miyano; Yukio Mizuno; Kiminori Tomimatsu; Kazumasa Hamamura; Muneo Takatani; Mitsuhiro Wakimasu

Abstract The 5-thia-1,8b-diazaacenaphthylenes ( 2 and its ester, 8 ) are new cyclazines, in which a paramagnetic ring is present in the peripheral 12π-electron ring system. Three convenient methods of preparing 8 have been developed. One involved thioglycolation of a new compound, 5-fluoroimidazo[1,2- a ]pyridine ( 6b ), followed by the Duff reaction gave 8 in 64% yield without chromatographic purification.


Tetrahedron | 2000

A Practical Synthesis of the Chronic Renal Disease Agent, 4,5-Dihydro-3H-1,4,8b-triazaacenaphthylen-3-one Derivatives, Using Regioselective Chlorination of Ethyl 5-methylimidazo[1,2-a]pyridine-3-carboxylate with N-Chlorosuccinimide

Tomomi Ikemoto; Tetsuji Kawamoto; Kiminori Tomimatsu; Muneo Takatani; Mitsuhiro Wakimasu

Abstract A convenient synthesis of the chronic renal disease agent, trifluoro-N-[4-(3-oxo-3,5-dihydro-4H-1,4,8b-triazaacenaphthylen-4-yl)butyl]methanesulfonamide (1a), for large scale has been developed via ethyl 5-(chloromethyl)imidazo[1,2-a]pyridine-3-carboxylate (3), which was given by the regioselective chlorination of ethyl 5-methylimidazo[1,2-a]pyridine-3-carboxylate (6) with N-chlorosuccinimide (NCS) using AcOEt as a solvent in 83% yield. The condensation of 3 and primary amines gave 4,5-dihydro-3H-1,4,8b-triazaacenaphthylen-3-one derivatives (1) in good yields. The present synthesis of 1a was accomplished in five steps from 2-amino-6-methylpyridine (4) without requiring a chromatographic method.


Tetrahedron | 2001

Convenient efficient synthesis of TAK-779, a nonpeptide CCR5 antagonist: development of preparation of various ammonium salts using trialkylphosphite and N-halogenosuccinimide

Tomomi Ikemoto; Atsuko Nishiguchi; Hiroyuki Mitsudera; Mitsuhiro Wakimasu; Kiminori Tomimatsu

Abstract A convenient and efficient synthesis of TAK-779 (1a), a nonpeptide CCR5 antagonist, has been achieved. The new methylation of tertiary amine (2) using trimethyl phosphite and N-chlorosuccinimide, followed by the addition of HCl led to ammonium chloride (1a) in 89% isolated yield without requiring a chromatographic method. By this preparation, ammonium methanesulfonate (1e) could be obtained in 75% isolated yield.


Tetrahedron Letters | 2000

Efficient syntheses of a novel 5-thia-1-azacycl[3.3.2]azine ring system and 3H-1,4-diazacycl[3.3.2]azine derivatives

Tetsuji Kawamoto; Kiminori Tomimatsu; Tomomi Ikemoto; Hidenori Abe; Kazumasa Hamamura; Muneo Takatani

Novel 5-thia-1-azacycl[3.3.2]azine derivatives 1 , 5-thia-1,8b-diazaacenaphthylenes, have successfully been prepared. An X-ray crystallographic analysis of 1c revealed that the 5-thia-1-azacycl[3.3.2]azine ring system adopts a planar structure as to the internal ring nitrogen atom. The 1 H NMR spectrum for unsubstituted ring system 1d implies contribution of a paramagnetic ring current in the peripheral 12π-electron ring system. Also, 3 H -1,4-diazacycl[3.3.2]azine derivatives, 4-benzyl-4,5-dihydro-3 H -1,4,8b-triazaacenaphthylen(e)-3-ones 2 and -3,5-diones 3 were synthesized with high efficiency via 3-(trichloroacetyl)imidazo[1,2- a ]pyridine derivatives as new useful synthetic intermediates.


Bioorganic & Medicinal Chemistry | 2015

Design and synthesis of a novel 2-oxindole scaffold as a highly potent and brain-penetrant phosphodiesterase 10A inhibitor

Masato Yoshikawa; Haruhi Kamisaki; Jun Kunitomo; Hideyuki Oki; Hironori Kokubo; Akihiro Suzuki; Tomomi Ikemoto; Kosuke Nakashima; Naomi Kamiguchi; Akina Harada; Haruhide Kimura; Takahiko Taniguchi

Highly potent and brain-penetrant phosphodiesterase 10A (PDE10A) inhibitors based on the 2-oxindole scaffold were designed and synthesized. (2-Oxo-1,3-oxazolidin-3-yl)phenyl derivative 1 showed the high P-glycoprotein (P-gp) efflux (efflux ratio (ER)=6.2) despite the potent PDE10A inhibitory activity (IC50=0.94 nM). We performed an optimization study to improve both the P-gp efflux ratio and PDE10A inhibitory activity by utilizing structure-based drug design (SBDD) techniques based on the X-ray crystal structure with PDE10A. Finally, 1-(cyclopropylmethyl)-4-fluoro-5-[5-methoxy-4-oxo-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-1(4H)-yl]-3,3-dimethyl-1,3-dihydro-2H-indol-2-one (19e) was identified with improved P-gp efflux (ER=1.4) and an excellent PDE10A inhibitory activity (IC50=0.080 nM). Compound 19e also exhibited satisfactory brain penetration, and suppressed PCP-induced hyperlocomotion with a minimum effective dose of 0.3mg/kg by oral administration in mice.


Chemical & Pharmaceutical Bulletin | 1995

Phosphorylation of Nucleosides with Phosphorus Oxychloride in Trialkyl Phosphate

Tomomi Ikemoto; Akira Haze; Hiroyuki Hatano; Yoshifumi Kitamoto; Masato Ishida; Kiyoshi Nara


Tetrahedron Letters | 2004

Asymmetric synthesis of (R)-(+)-6-(1,4-dimethoxy-3-methyl-2-naphthyl)-6-(4-hydroxyphenyl)hexanoic acid as a key intermediate for a neurodegenerative disease agent

Tomomi Ikemoto; Toshiaki Nagata; Mitsuhisa Yamano; Tatsuya Ito; Yukio Mizuno; Kiminori Tomimatsu


Heterocycles | 2001

Reactions with N-Chlorosuccinimide of Various 5-Methylimidazo[1,2-a]pyridine Derivatives with an Electron-withdrawing Group Substituted at the 3-Position

Tomomi Ikemoto; Mitsuhiro Wakimasu

Collaboration


Dive into the Tomomi Ikemoto's collaboration.

Top Co-Authors

Avatar

Kiminori Tomimatsu

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Tatsuya Ito

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Atsuko Nishiguchi

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Naohiro Fukuda

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Toshiaki Nagata

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Mitsuhiro Wakimasu

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Yasuhiro Sawai

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Kazuhisa Ishimoto

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Misayo Sera

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Takeshi Yamasaki

Takeda Pharmaceutical Company

View shared research outputs
Researchain Logo
Decentralizing Knowledge